Immune-Related Circulating miR-125b-5p and miR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients after Tumor Resection

• Main Authors: Eveline E. Vietsch, Ivana Peran, Mustafa Suker, Thierry P. P. van den Bosch, Fleur van der Sijde, Johan M. Kros, Casper H. J. van Eijck, Anton Wellstein
• Format: Article
• Language: English
• Published: MDPI AG 2019-11-01
• Series: Applied Sciences
• Subjects: pancreatic cancer; resection; circulating micrornas; biomarkers; progression free survival; immune cells
• Online Access: https://www.mdpi.com/2076-3417/9/22/4784

Clinical follow-up aided by changes in the expression of circulating microRNAs (miRs) may improve prognostication of pancreatic ductal adenocarcinoma (PDAC) patients. Changes in 179 circulating miRs due to cancer progression in the transgenic <i>Kras</i>^G12D/+; <i>Trp53</i>^R172H/+; <i>P48-Cre</i> (KPC) animal model of PDAC were analyzed for serum miRs that are altered in metastatic disease. In addition, expression levels of 250 miRs were profiled before and after pancreaticoduodenectomy in the serum of two patients with resectable PDAC with different progression free survival (PFS) and analyzed for changes indicative of PDAC recurrence after resection. Three miRs that were upregulated &#8805;3-fold in progressive PDAC in both mice and patients were selected for validation in 26 additional PDAC patients before and after resection. We found that high serum miR-125b-5p and miR-99a-5p levels after resection are significantly associated with shorter PFS (HR 1.34 and HR 1.73 respectively). In situ hybridization for miR detection in the paired resected human PDAC tissues showed that miR-125b-5p and miR-99a-5p are highly expressed in inflammatory cells in the tumor stroma, located in clusters of CD79A expressing cells of the B-lymphocyte lineage. In conclusion, we found that circulating miR-125b-5p and miR-99a-5p are potential immune-cell related prognostic biomarkers in PDAC patients after surgery.